ArticleEuropean journal of medical research2025
Ultrasound-guided adjunct to endovascular treatment of long-segment femoropopliteal chronic total occlusion.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTo describe the outcomes of endovascular treatment (EVT) using ultrasound (US) adjunct guidance for long-segment femoropopliteal chronic total occlusion (LSFP-CTO).
methodsThe medical record of 66 patients who underwent EVT, either conventional or US-guided, for LSFP-CTO recanalization at our institution between October 2016 and October 2023 was retrospectively reviewed. Baseline characteristics, procedural data, and clinical outcomes were analysed. Patency rates during post-procedural follow-up were evaluated using the Kaplan-Meier method.
resultsThe mean total lesion length was 242.08 ± 37.57 mm and 249.84 ± 46.52 mm in the conventional EVT and US-guided EVT groups, respectively (p > 0.05). Technical success was achieved in 30 patients (93.75%) in the conventional EVT and 32 patients (94.12%) in the US-guided EVT group. Among patients with successful EVT, procedural time and contrast usage were lower in the US-guided EVT group than in the conventional group. No immediate complications of acute renal failure were observed in the US-guided EVT group. During post-procedural follow-up, no significant difference was observed in the incidence of access site complications between the two groups (6.3% vs. 2.9%, p > 0.05). A significant reduction in Rutherford category and an increase in ankle-brachial index were observed after US-guided EVT. Furthermore, the cumulative primary patency rate at 2 years was 79.4% in the US-guided EVT group, with no statistically significant difference between the groups. The overall limb salvage rate was 88.2% at 2 years in the US-guided EVT group.
conclusionsUS-guided EVT is a feasible, safe, and effective adjunctive method for the treatment of LSFP-CTO, associated with low complication rates. This approach reduces procedural time and contrast usage while providing a real-time adjunctive technique for establishing arterial cannulation during EVT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.